earnings
confidence high
sentiment neutral
materiality 0.65
Artivion Q2 revenue $80.3M (+6% GAAP, +9% CC); net loss widens to $4.3M
ARTIVION, INC.
2022-Q2 EPS reported
-$0.19
revenue$157,553,000
- Revenue $80.3M vs $76.1M YoY; constant currency growth of 9%.
- GAAP net loss $4.3M ($0.11/sh) vs $2.2M ($0.06) YoY; non-GAAP net loss $1.3M ($0.03).
- Aortic stent graft revenue up 23% CC; On-X revenue up 12% CC; Asia Pacific +38% CC.
- Full-year 2022 constant currency revenue growth guidance reaffirmed at 9%-11%.
- Enrolled first patients in US AMDS clinical trial (PERSEVERE); expects FDA PMA approvals for PROACT Mitral and PerClot this year.